Evidence map›Paper›PMID 28265255›Full record

ReviewFrontiers in neurology2017

Mesenchymal Stem Cells in the Treatment of Traumatic Brain Injury.

Anwarul Hasan, George Deeb, Rahaf Rahal, Khairallah Atwi, Stefania Mondello, Hany Elsayed Marei, Amr Gali, Eliana Sleiman

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Stem Cell Therapy in Children with Traumatic Brain Injury.International journal of molecular sciences · 2023
    Review
  19. Review
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anwarul HasanDepartment of Mechanical and Industrial Engineering, Qatar University , Doha , Qatar.
George DeebBiomedical Engineering and Department of Mechanical Engineering, American University of Beirut , Beirut , Lebanon.
Rahaf RahalBiomedical Engineering and Department of Mechanical Engineering, American University of Beirut , Beirut , Lebanon.
Khairallah AtwiBiomedical Engineering and Department of Mechanical Engineering, American University of Beirut , Beirut , Lebanon.
Stefania MondelloDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina , Messina , Italy.
Hany Elsayed MareiBiomedical Research Center, Qatar University , Doha , Qatar.
Amr GaliBiomedical Engineering and Department of Mechanical Engineering, American University of Beirut , Beirut , Lebanon.
Eliana SleimanBiomedical Engineering and Department of Mechanical Engineering, American University of Beirut , Beirut , Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traumatic brain injury (TBI) is characterized by a disruption in the normal function of the brain due to an injury following a trauma, which can potentially cause severe physical, cognitive, and emotional impairment. The primary insult to the brain initiates secondary injury cascades consisting of multiple complex biochemical responses of the brain that significantly influence the overall severity of the brain damage and clinical sequelae. The use of mesenchymal stem cells (MSCs) offers huge potential for application in the treatment of TBI. MSCs have immunosuppressive properties that reduce inflammation in injured tissue. As such, they could be used to modulate the secondary mechanisms of injury and halt the progression of the secondary insult in the brain after injury. Particularly, MSCs are capable of secreting growth factors that facilitate the regrowth of neurons in the brain. The relative abundance of harvest sources of MSCs also makes them particularly appealing. Recently, numerous studies have investigated the effects of infusion of MSCs into animal models of TBI. The results have shown significant improvement in the motor function of the damaged brain tissues. In this review, we summarize the recent advances in the application of MSCs in the treatment of TBI. The review starts with a brief introduction of the pathophysiology of TBI, followed by the biology of MSCs, and the application of MSCs in TBI treatment. The challenges associated with the application of MSCs in the treatment of TBI and strategies to address those challenges in the future have also been discussed.

Indexed as

bone marrowcentral nervous systemmesenchymal stem cellsneuronstraumatic brain injury

Identifiers

PMID28265255
PMCPMC5316525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.